Development of a small alpha-synuclein-knockdown peptide as a potential therapy for Parkinson’s disease
Accumulating evidence supports the premise that reducing α-synuclein levels may be an effective and specific therapy for Parkinson’s disease. To date, a clinically applicable α-synuclein reducing therapeutic strategy has yet to be developed. To remedy this, I developed a blood brain barrier and plas...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2016
|
| Online Access: | http://hdl.handle.net/2429/58717 |